SRB 19
Alternative Names: SRB-19Latest Information Update: 16 Feb 2024
At a glance
- Originator SunRock Biopharma
- Class Antineoplastics; Bispecific antibodies; Immunotherapies; Recombinant fusion proteins
- Mechanism of Action Epidermal growth factor receptor antagonists; ERBB-3 receptor antagonists; Phosphorylation inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Cancer
Most Recent Events
- 20 Dec 2023 SunRock Biopharma has patent protection for HER3 targeted antibodies worldwide, prior to December 2023 (SunRock Biopharma webiste, December 2023)
- 20 Dec 2023 Preclinical trials in Cancer in Spain (Parenteral) (SunRock Biopharma pipeline, December 2023)
- 20 Dec 2023 Pharmacodynamics data from a preclinical study in Cancer released by SunRock Biopharma (SunRock Biopharma website, December 2023)